

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT8301257

|   |   |
|---|---|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT                                    |
| <b>NATURE OF CONVEYANCE:</b>  | ASSIGNMENT  |
| <b>CONVEYING PARTY DATA</b>   |   |
| <b>Name</b>   | <b>Execution Date</b>                             |
| MARK MILLS  | 02/07/2021  |
| ANDREW WILLIAM PHILLIPS   | 05/07/2021  |
| JON-PAUL WARD   | 02/07/2021  |
| <b>RECEIVING PARTY DATA</b>   |   |
| <b>Name:</b>  | SYGNATURE DISCOVERY LIMITED                       |
| <b>Street Address:</b>  | BIOCITY, PENNYFOOT STREET                         |
| <b>City:</b>  | NOTTINGHAM  |
| <b>State/Country:</b>   | UNITED KINGDOM                                    |
| <b>Postal Code:</b>   | NG1 1GR   |
| <b>PROPERTY NUMBERS Total: 1</b>  |   |
| <b>Property Type</b>  | <b>Number</b>                                     |
| Application Number:   | 18448696  |
| <b>CORRESPONDENCE DATA</b>  |   |
| <b>Fax Number:</b>  |   |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |   |
| <b>Phone:</b>   | 14154326000                                       |
| <b>Email:</b>   | IPDocketingBOS@mintz.com                          |
| <b>Correspondent Name:</b>  | MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, PC |
| <b>Address Line 1:</b>  | 44 MONTGOMERY STREET, 36TH FLOOR                  |
| <b>Address Line 4:</b>  | SAN FRANCISCO, CALIFORNIA 94104                   |
| <b>ATTORNEY DOCKET NUMBER:</b>  | 052691-504D01US                                   |
| <b>NAME OF SUBMITTER:</b>   | LISA NASH   |
| <b>SIGNATURE:</b>   | /lisa nash/                                       |
| <b>DATE SIGNED:</b>   | 11/29/2023  |
| <b>Total Attachments: 2</b>   |   |
| source=052691-504001US - Assignment_Mills_Ph#page1.tif  |   |
| source=052691-504001US - Assignment_Mills_Ph#page2.tif  |   |

**ASSIGNMENT**  
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a utility (provisional or non-provisional) patent application titled

“QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS”;

U.S. Application No. 17/353,567, filed June 21, 2021; and

International Application No. PCT/US2021/038218, filed June 21, 2021.

For good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:


1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to **Sygnature Discovery Limited**, a corporation of the United Kingdom, having a principal place of business at BioCity, Pennyfoot Street, Nottingham NG1 1GR, United Kingdom (“Assignee”), the entire right, title, and interest in and to:
  - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
  - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application, and any legal equivalent thereof in a foreign country or application for other rights based in whole or in part on the above-referenced patent application;
  - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) any legal equivalent thereof in a foreign country that are granted or issued upon, or that claim priority to any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and
  - (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including

provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.

2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.
6. Authorize **Corcept Therapeutics Incorporated**, or a representative thereof, to insert above the application numbers and filing dates of the above-described patent applications when known.

IN TESTIMONY WHEREOF, Assignors have signed their names on the date indicated:


Dated: 2/7/2021

  
Mark MILLS

Dated: 5/7/2021

  
Andrew William PHILLIPS

Dated: 2/7/2021

  
Jon-Paul WARD